Chang Ho Ahn

Chang Ho Ahn

Auto-generated profile, based on publicly available information

Chang Ho Ahn

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YBYeong Hak Bang
Yeong Hak Bang
CLChoong-Kun Lee
Choong-Kun Lee
KBKyunghye Bang
Kyunghye Bang
HKHyung-Don Kim
Hyung-Don Kim
KKKyu-pyo Kim
Kyu-pyo Kim
CYChanghoon Yoo
Changhoon Yoo
Purpose: Recently, anti-programmed cell death-1/anti-programmed cell death ligand-1 (anti-PD1/L1) immunotherapy has been demonstrated for its efficacy when combined with cytotoxic chemotherapy in randomized phase 3 trials for advanced biliary tract cancer (BTC). However, no biomarker predictive of benefit has been established for anti-PD1/L1 in BTC. Here, we evaluated tumor-infiltrating lymphocytes (TIL) using artificial intelligence-powered immune phenotype (AI-IP) analysis in advanced BTC treated with anti-PD1. Experimental Design: Pretreatment hematoxylin and eosin (H&E)–stained whole-slide images from 339 patients with advanced BTC who received anti-PD1 as second-line treatment or beyond, were employed for AI-IP analysis and correlative analysis between AI-IP and efficacy outcomes with anti-PD1. Next, data and images of the BTC cohort from The Cancer Genome Atlas (TCGA) were additionally analyzed to evaluate the transcriptomic and mutational characteristics of various AI-IP in BTC. Results: Overall, AI-IP were classified as inflamed [high intratumoral TIL (iTIL)] in 40 patients (11.8%), immune-excluded (low iTIL and high stromal TIL) in 167 patients (49.3%), and immune-desert (low TIL overall) in 132 patients (38.9%). The inflamed IP group showed a substantially higher overall response rate compared with the noninflamed IP groups (27.5% vs. 7.7%, P < 0.001). Median overall survival and progression-free survival were significantly longer in the inflamed IP group than in the noninflamed IP group (OS, 12.6 vs. 5.1 months; P = 0.002; PFS, 4.5 vs. 1.9 months; P < 0.001). In the TCGA cohort analysis, the inflamed IP showed increased cytolytic activity scores and IFNγ signature compared with the noninflamed IP. Conclusions: AI-IP based on spatial TIL analysis was effective in predicting the efficacy outcomes in patients with BTC treated with anti-PD1 therapy. Further validation is necessary in the context of anti-PD1/L1 plus gemcitabine–cisplatin.

1 June 2021 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
CAChang Ho Ahn
Chang Ho Ahn
CLChaelin Lee
Chaelin Lee
JSJaeyoon Shim
Jaeyoon Shim
Sung Hye KongSung Hye Kong
Sung Hye Kong
SKSu-jin Kim
Su-jin Kim
MCMan Ho Choi
Man Ho Choi

1 January 2019 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
CAChang Ho Ahn
Chang Ho Ahn
JBJae Hyun Bae
Jae Hyun Bae
YCYoung Min Cho
Young Min Cho
Ahn CH, et al. Diabetes Metab J. 2019 Jan;43:e39. https://doi.org/10.4093/dmj.2018.0202

20 September 2024 in Science Advances
Verified
Journal Article
Open access
JKJungHo Kong
JungHo Kong
XZXiaoyu Zhao
Xiaoyu Zhao
ASAkshat Singhal
Akshat Singhal
SPSungjoon Park
Sungjoon Park
RBRobin Bachelder
Robin Bachelder
TITrey Ideker
Trey Ideker
While immune checkpoint inhibitors have revolutionized cancer therapy, many patients exhibit poor outcomes. Here, we show immunotherapy responses in bladder and non–small cell lung cancers are effectively predicted by factoring tumor mutation burden (TMB) into burdens on specific protein assemblies. This approach identifies 13 protein assemblies for which the assembly-level mutation burden (AMB) predicts treatment outcomes, which can be combined to powerfully separate responders from nonresponders in multiple cohorts (e.g., 76% versus 37% bladder cancer 1-year survival). These results are corroborated by (i) engineered disruptions in the predictive assemblies, which modulate immunotherapy response in mice, and (ii) histochemistry showing that predicted responders have elevated inflammation. The 13 assemblies have diverse roles in DNA damage checkpoints, oxidative stress, or Janus kinase/signal transducers and activators of transcription signaling and include unexpected genes (e.g., PIK3CG and FOXP1) for which mutation affects treatment response. This study provides a roadmap for using tumor cell biology to factor mutational effects on immune response.

1 December 2025 in Cancer Research Communications
Verified
Journal Article
Open access
JPJongchan Park
Jongchan Park
SSSangwon Shin
Sangwon Shin
WHWoochan Hwang
Woochan Hwang
SKSeongho Keum
Seongho Keum
BBBiagio Brattoli
Biagio Brattoli
LMLuiza Moore
Luiza Moore
EGFR mutation screening in non–small cell lung cancer (NSCLC) remains variable globally and represents a significant care gap despite international recommendations and molecular testing guidelines. Recently, the use of deep learning (DL) methods to extract clinically actionable features from routine histology images has gained regulatory approval for multiple clinical applications. Therefore, the integration of predictive DL to complement molecular EGFR mutation screening may improve biomarker testing rates in NSCLC. To address this unmet need, we developed and validated Lunit SCOPE Genotype Predictor, a DL model trained and tuned using more than 12,000 whole-slide images, that predicts EGFR mutation status from routine hematoxylin and eosin images. Using a diverse dataset (n = 1,461) that captures histologic subtypes, multiple whole-slide scanners, different scan magnifications, and specimen types, we report an overall area under the ROC curve (AUROC) of 0.905. The model demonstrates robust performance across specimen types (biopsies and surgical resections, 0.804 and 0.912, respectively), histologic subtypes (adenocarcinoma and non-adenocarcinoma, 0.880 and 0.801, respectively), and EGFR mutation subtypes (AUROC, 0.854–0.931). Additionally, across a second independent test set (n = 599) sourced from 11 countries utilizing five different slide scanners, Lunit SCOPE Genotype Predictor achieved a robust AUROC of 0.860. Furthermore, across a multi-scanner test set (n = 2,261), EGFR mutation predictions were concordant in 90.4% of cases among five of six frequently used slide scanners. This validation across diverse clinical settings represents a vital step toward the application of artificial intelligence–based digital pathology tools in routine clinical practice to augment molecular EGFR mutation screening. Significance: DL predicts EGFR mutations in NSCLC from routine histology images, achieving an overall AUROC of 0.905 and 0.860 in two independent test sets across histologic subtypes, mutation subtypes, and imaging platforms.

28 February 2023 in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
CAChang Ho Ahn
Chang Ho Ahn
TOTae Jung Oh
Tae Jung Oh
SMSe Hee Min
Se Hee Min
YCYoung Min Cho
Young Min Cho
To maintain normal glucose homeostasis after a meal, it is essential to secrete an adequate amount of insulin from pancreatic β-cells. However, if pancreatic β-cells solely depended on the blood glucose level for insulin secretion, a surge in blood glucose levels would be inevitable after the ingestion of a large amount of carbohydrates. To avoid a deluge of glucose in the bloodstream after a large carbohydrate- rich meal, enteroendocrine cells detect the amount of nutrient absorption from the gut lumen and secrete incretin hormones at scale. Since insulin secretion in response to incretin hormones occurs only in a hyperglycemic milieu, pancreatic β-cells can secrete a “Goldilocks” amount of insulin (i.e., not too much and not too little) to keep the blood glucose level in the normal range. In this regard, pancreatic β-cell sensitivity to glucose and incretin hormones is crucial for maintaining normal glucose homeostasis. In this Namgok lecture 2022, we review the effects of current anti-diabetic medications on pancreatic β-cell sensitivity to glucose and incretin hormones.